References
- Lunenfeld B. Development of gonadotrophins for clinical use. Reprod Biomed Online 2002;4(Suppl 1):11–7
- Ludwig M, Felberbaum RE, Diedrich K, Lunenfeld B. Ovarian stimulation: from basic science to clinical application. Reprod Biomed Online 2002;5(Suppl 1):73–86
- Lunenfeld B. Treatment of anovulation by human gonadotropins. Int J Obstet Gynecol 1963;1:153–9
- Rosenberg E, Coleman J, Damani M, Garcia CR. Clinical effect of post menopausal gonadotropin. Clin Endocrinol Metab 1962;23:181–9
- Giudice E, Crisci C, Eshkol A, Papoian R. Composition of commercial gonadotrophin preparations extracted from human post-menopausal urine: characterization of non-gonadotrophin proteins. Hum Reprod 1994;9:2291–9
- Li TC, Hindle JE. Adverse local reaction to intramuscular injections of urinary-derived gonadotrophins. Hum Reprod 1993;8:1835–6
- Kauffman HF, Hovenga H, de Bruijn HW, Beintema JJ. Eosinophil derived neurotoxin (EDN) levels in commercial human urinary preparations of glycoprotein hormones. Eur J Obstet Gynecol Reprod Biol 1999;82:111–3
- Van de Weijer BH, Mulders JW, Bos ES, Verhaert PD, van den Hooven HW. Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reprod Biomed Online 2003;7:547–57
- Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72: 248–54
- Steelman SL, Pohley FM. Assay of the follicle stimulating hormone based on the augmentation with human chorionic gonadotropin. Endocrinology 1953;53:604–16